Cue Biopharma to Host Business Update Call and Webcast
August 02 2023 - 8:00AM
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of injectable
biologics to selectively engage and modulate disease-specific T
cells directly within the patient’s body, announced today that
it will host a conference call and webcast to provide a business
and clinical update on Wednesday, August 9, 2023 at 4:30 p.m. EDT.
Live and archived versions of the event can be accessed via the
Company’s website.
The company will provide a clinical update from its ongoing
Phase 1 trial evaluating CUE-101, the company’s lead interleukin 2
(IL-2)-based biologic from the CUE-100 series, in combination with
pembrolizumab (KEYTRUDA®) for patients with recurrent/metastatic
HPV+ head and neck cancer, as well as clinical progress from the
Phase 1 monotherapy dose escalation trial of the company’s second
clinical drug asset, CUE-102, for the treatment of patients with
Wilms’ Tumor 1 (WT1)-positive recurrent/metastatic cancers.
Additional clinical, pipeline and business updates will also be
addressed.
Webcast Details
Wednesday, August 9 at 4:30 p.m.
EDT
Investors: |
1-888-886-7786 |
|
International: |
1-416-764-8658 |
|
Conference
ID: |
92073568 |
|
Request a return call
via the Call me™ link: |
https://emportal.ink/3KcjfmW |
|
|
Participants can use the guest
dial-in numbers above and be answered by an operator or click the
Call me™ link for instant telephone access. The link will be active
15 minutes prior to the scheduled start time. |
|
Webcast: |
https://viavid.webcasts.com/starthere.jsp?ei=1626988&tp_key=38376b8c08 |
About Cue BiopharmaCue Biopharma, a
clinical-stage biopharmaceutical company, is developing a novel
class of injectable biologics to selectively engage and modulate
disease-specific T cells directly within the patient’s body. The
company’s proprietary platform, Immuno-STAT™ (Selective
Targeting and Alteration of T cells) and biologics are
designed to harness the body’s intrinsic immune system as T cell
engagers without the need for ex vivo manipulation or broad
systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an
experienced management team and independent Board of Directors with
deep expertise in immunology and immuno-oncology as well as the
design and clinical development of protein biologics.
For more information please
visit www.cuebiopharma.com and follow us on Twitter
at https://twitter.com/CueBiopharma.
Investor ContactMarie CampinellSenior Director,
Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactMaya RomanchukLifeSci
Communicationsmromanchuk@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From Apr 2024 to May 2024
Cue Biopharma (NASDAQ:CUE)
Historical Stock Chart
From May 2023 to May 2024